Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing mechanistic and clinical literature without systematic review methodology.
PubMed 24076269 · doi:10.1016/j.pharmthera.2013.09.004
What was done
This narrative review summarizes preclinical and clinical literature regarding the biological functions of interleukin-6 (IL-6), its pathological role in inflammation, autoimmunity, and malignancy, and the development of therapeutic monoclonal antibodies targeting IL-6 and its receptor.
What was found
No quantitative data, sample sizes, or numerical effect sizes are reported in the abstract. The abstract notes that tocilizumab (an anti-IL-6 receptor antibody) is clinically effective and approved for autoimmune and inflammatory diseases including rheumatoid arthritis, and that siltuximab (an anti-IL-6 antibody) has shown potential therapeutic benefits in human cancers as a single agent or combined with chemotherapy.
Why it matters
This paper outlines the therapeutic rationale for IL-6 pathway blockade as an immunotherapy strategy for inflammatory disorders and cancers refractory to conventional treatments.
Limits
This is a narrative review without systematic search criteria, explicit inclusion/exclusion protocols, risk of bias assessments, or quantitative meta-analytic pooling. Specific clinical trial endpoints, comparative effect sizes, and adverse events are not reported in the abstract.
Cited by
- supports Interleukin-6 (IL-6) is a pro-inflammatory cytokine that plays an important role in systemic inflammation.